

Inflammatory Condition Management Program



FOR MORE INFORMATION, PLEASE CONTACT:


More than 10 million patients in the United States live with a chronic inflammatory condition such as Rheumatoid Arthritis, Psoriasis, Crohn's Disease or Ulcerative Colitis. On average, the cost associated with the treatment of these conditions is approximately \$4,000+ per member per month. New agents to treat these conditions have been introduced to the market in the past few years and provide additional treatment options and higher costs.

Amwins Rx's active approach combines clinical guidelines with formulary and funding strategies to determine the best options to treat inflammatory conditions with multiple treatment choices available.

Our approach ensures a member has access to safe and effective treatment for their condition while the plan benefits from the most cost-effective, clinically appropriate formulary agent.

For example

If a patient is diagnosed with Rheumatoid Arthritis and is given a prescription for the biologic drug Enbrel, the medication will require a prior authorization (PA). As a part of the PA process, we review clinical guidelines, which state that the patient should first use a non-biologic medication such as methotrexate.



If the patient has already failed treatment or is unable to take a first-line medication such as methotrexate, our inflammatory condition management process would then direct the member to use a formulary preferred drug such as Humira. Using a formulary preferred drug allows us to apply rebates and other payment assistance programs that may not be available for non-formulary drugs.

